

To whom it may concern:

December 26, 2014
Nissan Chemical Industries, Ltd.

Bringing patent infringement actions concerning generic drugs of "LIVALO," a therapeutic agent for hypercholesterolemia (the fifth report)

Nissan Chemical Industries, Ltd. ("Nissan Chemical") filed complaints dated December 25, 2014 against Kyorin Rimedio Co., Ltd., and Sanwa Kagaku Kenkyusho Co., Ltd., which are generic drug marketing authorization holders of "LIVALO," with Osaka District Court seeking injunctive relief to cease and desist from infringing upon the patent rights relating to a certain crystal form of the API of "LIVALO" owned by Nissan Chemical (hereinafter "Patent Rights").

As announced earlier, Nissan Chemical had already filed similar complaints dated December 25, 2013, January 15, 2014, February 13, 2014, and March 4, 2014 against the entities below with Tokyo District Court seeking injunctive relief to cease and desist from infringing upon the Patent Rights.

Entities named in respective complaints of December 25, 2013:

Daito Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kobayashi Kako Co., Ltd., Meiji Seika Pharma Co., Ltd., Towa Pharmaceutical Co., Ltd., Tsuruhara pharmaceutical Co., Ltd., and Kaken Pharmaceutical Co., Ltd.

Entities named in respective complaints of January 15, 2014:

Sagami Chemical Industry Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., and Kotobuki Pharmaceutical Co., Ltd.

Entities named in respective complaints of February 13, 2014:

Yoshindo Inc., Nissin Pharmaceutical Co., Ltd., and Nippon Chemiphar Co., Ltd.

An entity named in a complaint of March 4, 2014:

Sawai Pharmaceutical Co., Ltd.

The present action is therefore the fifth legal action.

Nissan Chemical will in the future bring similar actions against any other entities as soon

as their infringement upon its intellectual property rights concerning “LIVALO” has been confirmed.

■ About “LIVALO”

“LIVALO” is a pharmaceutical whose API is invented and manufactured by Nissan Chemical, and Kowa Company Ltd. (Head office: Naka-ku, Nagoya-shi; President and Representative Director: Yoshihiro Miwa, hereinafter “Kowa”) is exclusively expanding its business globally (developing, manufacturing formulations, selling, and the business tie up with other companies, etc). In Japan, Kowa is to manufacture and sell the products under the brand names, “LIVALO Tablet 1mg; LIVALO Tablet 2mg; LIVALO Tablet 4mg/LIVALO OD Tablet 1mg; LIVALO OD Tablet 2mg; and LIVALO OD Tablet 4mg,” and Kowa Pharmaceutical Co. Ltd., is selling them. This pharmaceutical is ranked as a strong statin as a HMG-CoA reductase inhibitor which exhibits strong LDL cholesterol lowering activity. Besides its superior improvement effect against dislipidaemia, “LIVALO” is known by various supporting information to have characteristics, such as safety in long term use, less emergence of drug interactions, and clinical benefit with diabetic complication, etc., and is prescribed to many patients having dislipidaemia in Japan and also overseas.

Contact information for inquiries on the above
Corporate Planning Department Nissan Chemical Industries, Ltd. TEL: 03-3296-8320